Clinical Trials Logo

Acidosis, Lactic clinical trials

View clinical trials related to Acidosis, Lactic.

Filter by:

NCT ID: NCT05984186 Active, not recruiting - Exercise Clinical Trials

Wingate-type Exercise Test to Evaluate the Effect of High Velocity Therapy on Recovery Sensation and Blood Lactate Decline

Start date: March 6, 2023
Phase:
Study type: Observational

The study will evaluate the impact of high velocity therapy (HVT) on reduction of work of breathing (as implied by breath frequency) and enhanced blood lactate decline during recovery from a Wingate-type Exercise test. The study will include four study segments, corresponding to four different therapy settings.

NCT ID: NCT04975906 Completed - Critical Illness Clinical Trials

The Threshold of Serum Anion Gap as a Screening Tool for Organic Acidosis

Start date: July 1, 2017
Phase:
Study type: Observational

Background: The serum anion gap (AG) is commonly used as a screening tool for acid-base disorders. With modern laboratory techniques using ion-selective electrodes to measure the main electrolyte components of the AG, our definition high AG (HAGMA) should be reviewed. Aim: This study aims to assess the diagnostic value of AG and to determine a diagnostic threshold for HAGMA in a high-prevalence clinical setting. Method: Computerized extraction of anonymised data from electronic medical records was performed. A pre-defined criteria included all inpatients of an acute-care hospital who had measurements for organic acids (lactate, ketone or salicylate) paired with a serum urea, electrolyte and creatinine panel.

NCT ID: NCT04948138 Completed - MELAS Syndrome Clinical Trials

Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome

Start date: June 28, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assesses the efficacy of oral supplementation with glutamine over three months on several amino acids and lactate concentration measured in cerebrospinal fluid and cerebral lactate measured by magnetic resonance spectroscopy.

NCT ID: NCT04766008 Recruiting - Clinical trials for Coronary Artery Disease

Metformin in Diabetic Patients Undergoing Coronary Angiography

NO-STOP
Start date: January 15, 2020
Phase: Phase 4
Study type: Interventional

The present study aims to evaluate the strict application of the 2018 European Society of Cardiology guidelines on myocardial revascularization, that recommends to check renal function if patients have taken metformin immediately before angiography and withhold metformin if renal function deteriorates. The aim of this study is to assess the safety of metformin in diabetic patients undergoing coronary angiography in terms of risk of lactic acidosis and to individuate eventual predictors of augmented lactate after coronary angiography.

NCT ID: NCT04762966 Recruiting - Clinical trials for Metformin Associated Lactic Acidosis

Study of Metformin Overdose

METINFO
Start date: March 1, 2021
Phase:
Study type: Observational

The objective of the METINFO study is an observational single-center retrospective and descriptive study. The main objective is to estimate the real mortality rate associated to a Metformin overdose. Second objectives are to estimate the real hospitalization rate related to metformin overdose and to identify the risk factors of a metformin overdose and especially the potential correlation between metformin blood concentration and overdose severity.

NCT ID: NCT04604548 Completed - Clinical trials for Mitochondrial Diseases

The KHENEREXT Study

Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202. In the KH176-203 study subjects will be receiving KH176 100 mg BID or KH176 50 mg bid in die (BID) (as determined by the investigator based on safety / tolerability considerations) for a year, thereby ensuring continued treatment with KH176 after study KH176-202. A final follow-up visit is scheduled 4 weeks after the intake of the last dose of study medication for patients not rolling over into the compassionate use program. Primary safety data and secondary efficacy (endpoint) data will be monitored and reviewed every three months by an independent Data Safety Monitoring Board (DSMB) to evaluate potential risks and benefits.

NCT ID: NCT04475549 Terminated - MELAS Clinical Trials

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Start date: November 13, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.

NCT ID: NCT03723993 Withdrawn - Lactic Acidosis Clinical Trials

Remote Ischemic Preconditioning During Cardiopulmonary Bypass

RIPC
Start date: January 15, 2018
Phase: N/A
Study type: Interventional

The objective of study is to detect effect of remote ischemic preconditioning on serum lactate levels during and after cardiac surgery with cardiopulmonary bypass in addition to its effect on cardiac and renal clinical outcomes.

NCT ID: NCT03522181 Completed - Clinical trials for Liver Transplantation

Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation

GIK
Start date: February 2016
Phase: N/A
Study type: Interventional

Lactic acidosis is a common phenomenon occurring during orthotopic liver transplantation (OLT), especially during the anhepatic and early postreperfusion phases. However, little drugs effectively decrease the degree of lactic acidosis when it happens. The aim of this study is to explore whether glucose-Insulin-Potassium(GIK) infusion can relieve metabolic acidosis and improve perioperative outcome in patients undergoing OLT.

NCT ID: NCT03466528 Completed - Alcohol Withdrawal Clinical Trials

Alcohol: Thiamine and or Magnesium 1

AToM1
Start date: December 16, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE). Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the Accident & Emergency (A&E) department, however routine co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. Without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat WE. This study is designed to determine if administration of magnesium to AUD patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.